HK1208805A1 - Inhibitors of beta hydrolase for treatment of cancer - Google Patents
Inhibitors of beta hydrolase for treatment of cancerInfo
- Publication number
- HK1208805A1 HK1208805A1 HK15109523.0A HK15109523A HK1208805A1 HK 1208805 A1 HK1208805 A1 HK 1208805A1 HK 15109523 A HK15109523 A HK 15109523A HK 1208805 A1 HK1208805 A1 HK 1208805A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- cancer
- treatment
- beta hydrolase
- hydrolase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704014P | 2012-09-21 | 2012-09-21 | |
| PCT/US2013/061050 WO2014047519A2 (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydrolase for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208805A1 true HK1208805A1 (en) | 2016-03-18 |
Family
ID=50342080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109523.0A HK1208805A1 (en) | 2012-09-21 | 2015-09-29 | Inhibitors of beta hydrolase for treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9771356B2 (es) |
| EP (2) | EP2897607B1 (es) |
| JP (1) | JP6469009B2 (es) |
| KR (1) | KR102137180B1 (es) |
| CN (2) | CN110818660B (es) |
| AU (1) | AU2013317791B2 (es) |
| CA (1) | CA2885762C (es) |
| ES (2) | ES2865412T3 (es) |
| HK (1) | HK1208805A1 (es) |
| WO (2) | WO2014047519A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2897607B1 (en) | 2012-09-21 | 2017-11-22 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
| US10961320B2 (en) | 2018-06-18 | 2021-03-30 | Midwestern University | Monoclonal antibodies targeting epitopes of ASPH |
| CN109364251A (zh) * | 2018-12-06 | 2019-02-22 | 苏州大学 | Tet蛋白在治疗抑郁症中的应用 |
| CN113924088A (zh) * | 2019-02-15 | 2022-01-11 | 中西部大学 | 同位素稳定的特窗酰亚胺化合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD39717A (es) | ||||
| DE39717C (de) | H. LEHMANN in München, Enhuberstr. 5 part | Bleistifthalter | ||
| WO1987000729A1 (en) | 1985-08-02 | 1987-02-12 | Chevron Research Company | Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans |
| US5314913A (en) | 1992-12-08 | 1994-05-24 | American Home Products Corporation | 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones |
| US5698585A (en) | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
| JPH09110853A (ja) * | 1995-10-12 | 1997-04-28 | Kikkoman Corp | ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法 |
| UA57002C2 (uk) * | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| JP2001514668A (ja) | 1997-03-14 | 2001-09-11 | メルク フロスト カナダ アンド カンパニー | Ｃｏｘ−２阻害薬としての酸素連結部を有する（メチルスルホニル）フェニル−２−（５ｈ）−フラノン類 |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| WO2003018575A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase |
| US6667330B2 (en) * | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| AU2002950862A0 (en) | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| MXPA05004033A (es) * | 2002-10-16 | 2005-06-08 | Isis Innovation | Hidroxilasas de asparaginil y moduladores de las mismas. |
| ATE552251T1 (de) * | 2004-01-09 | 2012-04-15 | Lilly Co Eli | Thiophen- und furanverbindungen |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| SG186229A1 (en) * | 2010-06-07 | 2013-01-30 | Novomedix Llc | Furanyl compounds and the use thereof |
| EP2897607B1 (en) | 2012-09-21 | 2017-11-22 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
-
2013
- 2013-09-20 EP EP13838498.7A patent/EP2897607B1/en active Active
- 2013-09-20 CN CN201910949656.0A patent/CN110818660B/zh active Active
- 2013-09-20 EP EP17202827.6A patent/EP3345596B1/en active Active
- 2013-09-20 WO PCT/US2013/061050 patent/WO2014047519A2/en active Application Filing
- 2013-09-20 AU AU2013317791A patent/AU2013317791B2/en active Active
- 2013-09-20 ES ES17202827T patent/ES2865412T3/es active Active
- 2013-09-20 ES ES13838498.7T patent/ES2660822T3/es active Active
- 2013-09-20 JP JP2015533237A patent/JP6469009B2/ja active Active
- 2013-09-20 CA CA2885762A patent/CA2885762C/en active Active
- 2013-09-20 WO PCT/US2013/060934 patent/WO2014047447A2/en active Application Filing
- 2013-09-20 CN CN201380061004.4A patent/CN104902889A/zh active Pending
- 2013-09-20 US US14/430,101 patent/US9771356B2/en active Active
- 2013-09-20 KR KR1020157010188A patent/KR102137180B1/ko active IP Right Grant
-
2015
- 2015-09-29 HK HK15109523.0A patent/HK1208805A1/xx unknown
-
2017
- 2017-07-17 US US15/651,842 patent/US10106532B2/en active Active
- 2017-09-26 US US15/715,989 patent/US10710995B2/en active Active
-
2018
- 2018-09-14 US US16/131,275 patent/US10351555B2/en active Active
-
2019
- 2019-06-12 US US16/439,253 patent/US10787445B2/en active Active
-
2020
- 2020-06-02 US US16/890,680 patent/US20200361925A1/en not_active Abandoned
- 2020-09-23 US US17/029,127 patent/US20210032233A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,472 patent/US20220251076A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288181A (en) | Cancer treatment methods | |
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| IL237791A0 (en) | A method for treating cancer | |
| IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
| SG11201503893RA (en) | Method of treating cancer | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
| HK1208805A1 (en) | Inhibitors of beta hydrolase for treatment of cancer | |
| HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
| EP2928456A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IL237229A0 (en) | Methods of treating cancer using lipoplatin |